Akfen Yenilenebilir Enerji A.S. (AKFYE) - Total Liabilities

Latest as of September 2024: TL16.84 Billion TRY ≈ $377.16 Million USD

Based on the latest financial reports, Akfen Yenilenebilir Enerji A.S. (AKFYE) has total liabilities worth TL16.84 Billion TRY (≈ $377.16 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Akfen Yenilenebilir Enerji A.S. operating cash flow efficiency to assess how effectively this company generates cash.

Akfen Yenilenebilir Enerji A.S. - Total Liabilities Trend (2020–2023)

This chart illustrates how Akfen Yenilenebilir Enerji A.S.'s total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of Akfen Yenilenebilir Enerji A.S. for net asset value and shareholders' equity analysis.

Akfen Yenilenebilir Enerji A.S. Competitors by Total Liabilities

The table below lists competitors of Akfen Yenilenebilir Enerji A.S. ranked by their total liabilities.

Company Country Total Liabilities
Wowprime Corp
TW:2727
Taiwan NT$10.89 Billion
Dateline Resources Ltd
AU:DTR
Australia AU$4.38 Million
Taiyuan Lionhead Cement Co Ltd
SHG:600539
China CN¥115.83 Million
Sichuan Etrol Technologies Co Ltd
SHE:300370
China CN¥779.86 Million
Anhui Jiuhuashan Tourism Dvlp
SHG:603199
China CN¥297.59 Million
ATRenew Inc DRC
NYSE:RERE
USA $1.41 Billion
Beijing Changjiu Logistics Ltd
SHG:603569
China CN¥2.80 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥247.20 Million

Liability Composition Analysis (2020–2023)

This chart breaks down Akfen Yenilenebilir Enerji A.S.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AKFYE stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.18 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.56 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.36 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Akfen Yenilenebilir Enerji A.S.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Akfen Yenilenebilir Enerji A.S. (2020–2023)

The table below shows the annual total liabilities of Akfen Yenilenebilir Enerji A.S. from 2020 to 2023.

Year Total Liabilities Change
2023-12-31 TL14.15 Billion
≈ $316.87 Million
-23.30%
2022-12-31 TL18.44 Billion
≈ $413.12 Million
+103.32%
2021-12-31 TL9.07 Billion
≈ $203.19 Million
+60.01%
2020-12-31 TL5.67 Billion
≈ $126.98 Million
--

About Akfen Yenilenebilir Enerji A.S.

IS:AKFYE Turkey Utilities - Renewable
Market Cap
$590.84 Million
TL26.38 Billion TRY
Market Cap Rank
#11689 Global
#105 in Turkey
Share Price
TL22.26
Change (1 day)
+1.55%
52-Week Range
TL15.23 - TL24.06
All Time High
TL31.78
About

Akfen Yenilenebilir Enerji A.S. engages in the production of renewable energy in Turkey. It operates a portfolio of wind and hybrid solar power plants with a total installed capacity of 423.9 megawatts; hydroelectric plants with a capacity of 228.7; and solar power plants with an installed capacity of 121.4 megawatts. The company was founded in 2007 and is based in Ankara, Turkey. Akfen Yenileneb… Read more